View PDS Biotechnology Corp. PDSB stock quote prices, financial information, real-time forecasts, and company news from CNN.

PDS Biotechnology (NASDAQ:PDSB), a clinical-stage immunotherapy company focused on innovative oncology and infectious disease solutions, released its second quarter results on August 13, 2025, for the ...

PDS Biotechnology PDSB shares are up on Wednesday as the company announced the publication of clinical and immunological biomarker data from Stage 1 of a Phase 2 trial of PDS01ADC in the Journal of ...

The trial focused on patients with microsatellite-stable or mismatch repair-proficient metastatic colorectal cancer with liver metastases ・The treatment delivered an ORR of nearly 78%, compared to 35% ...

Fintel reports that on November 25, 2025, B. Riley Securities maintained coverage of PDS Biotechnology (NasdaqCM:PDSB) with a Buy recommendation. As of November 17, 2025, the average one-year price ...

Detailed price information for Pds Biotechnology Corp (PDSB-Q) from The Globe and Mail including charting and trades.

PDS Biotechnology Corporation (NASDAQ:PDSB) unveiled compelling new data on its Versamune HPV (PDS0101) immunotherapy at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The ...

PDS Biotechnology Corporation (NASDAQ:PDSB) is a clinical-stage biopharma company that specializes in the development of cancer immunotherapies. The company’s main drug, PDS0101, is in Phase II trials ...

Detailed price information for Pds Biotechnology Corp (PDSB-Q) from The Globe and Mail including charting and trades.

This period saw the company reduce total operating expenses by 12.6% (GAAP), driven mainly by lower personnel and professional service fees. Research and development, or R&D, costs (GAAP) decreased ...